12.22.2013 - By Billy Lin, MD and Tina Lien, BSc Pharm
We reviewed the CDA 2013 guidelines on antihyperglycemic therapy for type 2 diabetes (http://guidelines.diabetes.ca/executivesummary/ch13), and explored the pharmacological properties of each of the major classes:
Biguanides: Metformin
Sulfonylureas: chlorpropamide, gliclazide, glimepiride, glyburide, and tolbutamide
Thiazolidinediones: pioglitazone and rosiglitazone
Meglitinides: Nateglinide and repaglinide
Alpha-glucosidase inhibitors: Acarbose
Dipeptidyl Peptidase-4 inhibitors (DPP4 inhibitors): Saxagliptin and sitagliptin
Glucagon Like Peptide-1 Analogues (GLP-1 analogues): Liraglutide and Exenatide
Drug information:
Drug monographs
CPS: http://www.e-therapeutics.ca/
Therapeutic Choices: http://www.e-therapeutics.ca/
Rx Files: http://www.rxfiles.ca/rxfiles/modules/druginfoindex/druginfo.aspx